Colossal Biosciences, known for its de-extinction efforts, is reportedly in discussions to raise new capital that could elevate its valuation to between $20 billion and $30 billion. The company previously held a valuation of $10.2 billion and has been developing technologies aimed at conservation and biological innovation.